DALLAS/FORT WORTH, Texas--(BUSINESS WIRE)--Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company with a late-stage pipeline of innovative extended-release (XR) product candidates for the treatment of attention deficit hyperactivity disorder (ADHD), today announced that Vipin Garg, Ph.D., President and CEO will present at the 14th Annual BIO Investor Forum taking place in San Francisco October 20-21. Dr. Garg’s presentation is scheduled for Tuesday, October 20 at 4:30 p.m. Pacific Time, 7:30 p.m. Eastern Time.
A live webcast will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/. A replay will be available on the company’s website for thirty days following the event.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platform. The Company is initially focusing on ADHD and has developed three branded product candidates that are XR medications in patient-friendly orally disintegrating tables or liquid suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®1, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
1 Tussionex® is a registered trademark of the UCB Group of Companies
For Neos Therapeutics:
Richard I. Eisenstadt, 972-408-1389
Chief
Financial Officer
reisenstadt@neostx.com
or
Lazar
Partners
David Carey, 212-867-1768
Investor Relations
dcarey@lazarpartners.com
